The present disclosure relates to a carmabinoid derivative, a pharmaceutical composition comprising it, as well as its use in the treatment and prevention of diseases associated with a carmabinoid receptor in a subject in need thereof, such as acute pain, ADHD/ ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, etc. The carmabinoid derivative has the following formula:
spectroscopy. The influence of the structural changes of the nanoclusters and the effect of the simultaneous presence of Lewis and Brönsted acid sites were evaluated studying the product distribution from the α-pinene oxide isomerization reaction. It was determined that the Brönsted acidity of the Fe/MCM-41 system has not the sufficient acid strength to modify the product distribution which is mainly governed
合成具有高铁分散性的系统Fe 2 O 3 / MCM-41,以将路易斯酸位引入MCM-41结构中。两种煅烧气氛(惰性和氧化剂)用于生产具有不同结构特性的铁纳米团簇。此外,在两种固体上均实现了甲硅烷基化处理,目的是中和与MCM-41硅烷醇基团相关的布朗斯台德酸度。通过原子吸收光谱,低角度X射线衍射,N 2吸附,程序升温还原,傅里叶变换红外光谱,29个核磁共振对样品进行表征Si和Mössbauer光谱。研究了α-pine烯氧化物异构化反应的产物分布,评估了纳米团簇的结构变化的影响以及路易斯和布朗斯台德酸位点同时存在的影响。已经确定,Fe / MCM-41系统的布朗斯台德酸度没有足够的酸强度来改变主要由路易斯位点控制的产物分布。
BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
申请人:SENOMYX, INC.
公开号:US20160376263A1
公开(公告)日:2016-12-29
The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.
NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY
申请人:Kannalife, Inc.
公开号:US20160311769A1
公开(公告)日:2016-10-27
Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.